05:47 PM EDT, 03/21/2024 (MT Newswires) -- Adverum Biotechnologies ( ADVM ) on Thursday filed a registration statement with the US Securities and Exchange Commission for the potential sale of up to $200 million of its securities from time to time in one or more offerings.

The filing covers common stock, preferred stock, debt securities and warrants.

The company said net proceeds from the sale will be used for working capital, capital expenditures and general corporate purposes.

Adverum shares fell 2.7% in recent after-hours trading.

Price: 14.35, Change: -0.4, Percent Change: -2.71